Daniel Mikol M.D.

Daniel Mikol, MD, PhD, currently serves as Chief Medical Officer at NervGen Pharma Corp., overseeing Phase 1 trials and proof-of-concept study designs with a focus on spinal cord injury. Previous roles include Executive Medical Director of Global Development at Amgen, leading clinical development in Neuroscience and Nephrology, and Senior Medical Director at Biogen, where clinical development for Natalizumab/Tysabri was managed. Daniel Mikol also held positions at Novartis Consumer Health and EMD Serono, Inc., including leadership roles in medical affairs and clinical development. Early career experience includes serving as Associate Professor and Director of the Multiple Sclerosis Center at Michigan Medicine, with a focus on patient care and clinical trials. Education includes a neurology residency at the University of California, San Francisco, and an MD and PhD from The University of Chicago Pritzker School of Medicine, complemented by a Fulbright Scholarship in Germany.